Achaogen’s bankruptcy and going-out-of-business sale offer a grim cautionary tale for the future of antibiotic development
The lights are winking out at Achaogen, offering another cautionary tale that will make it even less likely we’ll see new companies come along to develop antibiotics — even as drug-resistant strains of bacteria pose a rising threat to the world’s population.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,100+ biopharma pros reading Endpoints daily — and it's free.